StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Kiniksa Pharmaceuticals International's price to sales ratio was 9.3× on Nov 11, 2026, against 5.4× a year earlier. Over the last 5 years it ranged from 3.4× to 18.2×, with a median of 5.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20269.3×+4.0
2025Dec 31, 20255.3×+1.5
2024Dec 31, 20243.7×−1.2
2023Dec 29, 20235.0×−0.9
2022Dec 30, 20225.9×–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?